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The role of inflammation in cancer has been reported in various adult malignant neoplasms. By contrast, its role in
pediatric tumors has not been as well studied. In this study, we have identified and characterized the infiltration of
various inflammatory immune cells as well as inflammatory markers in Wilms tumor (WT), the most common renal
malignancy in children. Formalin-fixed paraffin-embedded blocks from tumors and autologous normal kidneys
were immunostained for inflammatory immune cells (T cells, B cells, macrophages, neutrophils, and mast cells)
and inflammatory markers such as cyclooxygenase-2 (COX-2), hypoxia-inducible factor 1α, phosphorylated STAT3,
phosphorylated extracellular signal–related kinases 1 and 2, inducible nitric oxide synthase, nitrotyrosine, and
vascular endothelial growth factor expression. Overall, we found that there was predominant infiltration of tumor-
associated macrophages in the tumor stroma where COX-2 was robustly expressed. The other tumor-associated
inflammatory markers were also mostly localized to tumor stroma. Hence, we speculate that COX-2–mediated
inflammatory microenvironment may be important in WT growth and potential therapies targeting this pathway
may be beneficial and should be tested in clinical settings for the treatment of WTs in children.
Translational Oncology (2014) 7, 484–492Address all correspondence to: Dr. Paramahamsa Maturu, Ph.D, Department of Pediatrics,
Section of Neonatology, Texas Children's Hospital, Baylor College of Medicine, 1102 Bates
Avenue, MC: FC520, Houston, TX 77030, USA. E-mail: maturu@bcm.edu
1This article refers to supplementary materials, which are designated by Tables W1 to
W3 and Figure W1 and are available online at www.transonc.com.
2This work was supported by US National Institutes of Health grants CA34936 and
DK069599 and by State of Texas Cancer Prevention Research Institute of Texas (CPRIT)
grants RP110324 and RP100329 (V.H.). This work was partially supported by grants from
the MD Anderson Cancer Center Specialized Programs of Research Excellence (SPORE) in
Melanoma P50CA093459 (E.A.G. and S.E.), by theMDAndersonCancer Center Support
grant P30 CA016672, and by the Dr Miriam and Sheldon G. Adelson Medical Research
Foundation (E.A.G. and S.E.). The authors declare that there are no conflicts of interest.
Received 11 March 2014; Revised 10 May 2014; Accepted 21 May 2014
© 2014TheAuthors. PublishedbyElsevier Inc. onbehalf ofNeoplasia Press, Inc.This is an open
access article under theCCBY-NC-NDlicense (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1936-5233/14
http://dx.doi.org/10.1016/j.tranon.2014.05.008Introduction
The importance of inflammation in tumor development is well
known, and it is apparent that an inflammatory microenvironment is
a key component of many tumors, even when a clinical association
with inflammation is not yet demonstrated [1–3]. During the past
decade, studies using cell-specific knockout animals have elucidated
mechanisms by which inflammation leads to cancer [4]. Inflamma-
tion is initiated by the recruitment of a wide range of inflammatory
immune cells, which induce tumor cells to produce inflammatory
mediators such as chemokines and cytokines, reactive oxygen and
nitrogen species, and various other bioactive molecules, which work
in an autocrine and/or paracrine manner [2]. In some instances,
genetic as well as epigenetic modifications can also establish an
Table 1. Number of Sections that Stained Positive for Each Immune Cell Type and Inflammatory Marker Analyzed
CD3 CD20 TAM TIN MC COX-2 HIF-1 p-Stat3 p-ERK1/2 iNOS NT VEGF
10/14 7/14 13/14 12/14 12/14 12/12 7/7 10/13 10/14 11/13 13/13 13/13
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Thus, there exists a delicate balance between antitumor immunity
and tumor-promoting immune activity within the tumor microen-
vironment, involving tumor cells, stroma (including fibroblasts and
endothelial cells), and innate and adaptive immune cells.
The role of an inflammatory microenvironment in tumor
development has been investigated primarily in adult-onset cancers,
often those for which inflammation is a known risk factor. Little is
known about the role of an inflammatory microenvironment in the
development and growth of childhood tumors. Wilms tumor (WT) is
a childhood cancer of the kidney that is thought to be largely a result
of genetic alterations, variably including mutations in the WT1,
CTNNB1, and/or WTX1 genes. Vascular endothelial growth factor
(VEGF) and hypoxia-inducible factor 1 (HIF-1), two proteins that
are upregulated in the inflammatory environment and recruit
inflammatory immune cells, have been observed in WT [5]. In a
comparative analysis with adult tumors, infiltration of macrophages [6]
was reported along with ubiquitous expression of cyclooxygenase-2
(COX-2) in a small set of pediatric tumors (including five WTs), and
this infiltration and expression were independent of the type of
neoplasm [7,8]. However, these studies were restricted to only one
inflammatory marker, and none of the studies provided a comprehen-
sive view of the inflammatory microenvironment in pediatric tumors or
correlated the presence of these markers with inflammation in WT.
To learn more about the role of the inflammatory microenvironment
in the development ofWT, we analyzed tumors for various inflammatory
markers and inflammatory immune cells by immunohistochemical
(IHC) staining. Overall, we found that WT exhibited infiltration of
inflammatory immune cells and overexpression of several inflammatory
transcription factors and other inflammatory markers compared with
normal kidneys. Our data suggest that a COX-2–mediated inflamma-
tory microenvironment may be important in WT tumorigenesis and
that investigating the potential utility of therapeutic targeting of this
environment is warranted.Materials and Methods
Tissue Samples
Pretreatment tumor tissues and autologous normal kidney
specimens were obtained from 16 WT patients aged 7 to 66 months
at the time of diagnosis. Informed consent was obtained from each
patient’s parent or guardian. Studies were approved by the Ins-
titutional Review Board and in accordance with an assurance filed
with and approved by the US Department of Health and Human
Services. Eight of the patients were males and eight were females, and
one patient had bilateral disease. Of these 16 patients, 4 were at stage
IV, 4 were at stage III, 3 were at stage II, and 5 were at stage I of WT
disease. Tissues were fixed in formalin and embedded in paraffin
(FFPE) in preparation for analysis.
Mouse Tumor Tissues
Amousemodel for the humanWThas been generated in our laboratory
[9] by Wt1 gene ablation and insulin-like growth factor 2 (IGF2) up-
regulation by conditional knockout strategy (Wt1−/flH19+/−mCre-ERTM orWt1-IGF2mice). These mice developed tumors at the age of 3 months on
an average. The tumors and normal kidneys from its littermate controls
were collected at the similar age and processed as mentioned earlier for
histology and IHC analysis.
Histology and IHC of Immune Cell Markers
FFPE specimens were cut in 5-μm sections, which were stained
with hematoxylin and eosin. For IHC analysis, FFPE sections were
deparaffinized in xylene, rehydrated sequentially in ethanol (100%,
90%, and 70%), and placed into a 1% phosphate-buffered saline
solution (PBS; pH 7.4). Tissues were analyzed for infiltration by T cells,
B cells, macrophages, neutrophils, and mast cells (MCs). Inflammatory
markers analyzed were COX-2, HIF-1, phosphorylated extracellular
signal–related kinases 1 and 2 (p-ERK1/2), phosphorylated STAT3
(p-Stat3), inducible nitric oxide synthase (iNOS), nitrotyrosine
(NT), and VEGF. Simultaneously, to prove the similar expression
and infiltration pattern in the mouse model of WT, mouse tumor
tissues and control kidneys were immunostained for inflammatory
marker COX-2 and predominant inflammatory immune cells, macro-
phages (F4/80). Details of antibody staining and epitope retrieval are
summarized in Table W1.
Tissues known to contain the antigen of interest were identified and
used as positive controls to optimize IHC staining by testing antigen
retrieval methods and times and by titrating antibody dilutions. A
positive control tissue slide was included in each batch of immuno-
staining. Negative controls were tissue sections not treated with the
primary antibody. The numbers of sections assessed for each tumor for
different immune cells and inflammatory protein markers are indicated
in Table 1. Because of limitations in the amount of tumor tissue
available, IHC data could not be obtained for all tumors.
MC Staining
MC infiltration in tumors and normal kidneys was assessed by
quantification of chloroacetate esterase (Cat. No. 91C kit; Sigma
Chemical Co, St Louis, U.S.A.). Briefly, immediately before fixation, 1
ml of sodium nitrite solution was added to 1 ml of Fast Red Violet LB
base solution in a test tube and mixed gently by inversion and allowed
to stand for 2 minutes. This solution was added to 40 ml of prewarmed
(at 37°C) deionized water and then to 5 ml of Trizmal 6.3 buffer
concentrate; afterwards, 1 ml of naphthol AS-D chloroacetate solution
was added to obtain a red colored solution that was transferred into a
Coplin jar. Slides were fixed in citrate acetone formaldehyde solution at
room temperature (23-26°C) for 30 seconds. Slides were rinsed in
running water for 45 to 60 seconds and incubated in previously
prepared red colored solution for 15 minutes in Coplin jar at 37°C
protected from light. Slides were rinsed with deionized water for 2
minutes and counterstained by Mayer’s hematoxylin (Fisher Scientific,
Fair Lawn, NJ) and mounted by aqueous mounting media. After
drying, slides were evaluated microscopically.
Double Immunofluorescence Analysis
To examine the co-distribution of inflammatory marker COX-2
and tumor-associated macrophage (TAM) infiltration in the tumor
stroma, a double immunofluorescence staining was carried out.
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Figure 1. Localization of adaptive immune cell infiltration primarily in the stroma of WTs. (A–C) Representative CD3+ T cell infiltration on
IHC analysis of (A) normal kidney, (B) tumor blastema, and (C) and tumor stroma. (D) Quantification of average number of CD3+ cells per
field in normal kidneys (K) and tumors (T). (E–G) Representative CD20+ B cell infiltration on IHC analysis of (E) normal kidney, (F) tumor
blastema, and (G) tumor stroma. (H) Quantification of average number of CD20+ cells per field in kidneys and tumors. *P ≤ .05.
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heating for 45 minutes in 1 mMTris EDTA, pH 9.0 buffer in a water
bath at 95 to 100°C. The sections were left at room temperature in
the buffer for 1 hour to cool down followed by washing three times
with 1× PBS for 5 minutes each and were incubated with 1% BSA to
block nonspecific protein binding. Sections were incubated overnight
with amixture of two primary antibodies [formacrophages, monoclonal
mouse anti-human CD68 at 1:50 dilution (Dako, Glostrup, Denmark;
Cat. No. M0814); for COX-2, polyclonal goat anti-human COX-2,
1:100 dilution (Santa Cruz Biotechnology, Dallas, Texas; SC-1747)] in
1% BSA in a humidified chamber at 4°C. After washing with 1× PBS
three times, sections were incubated with a mixture of Alexa Fluor goat
anti-mouse 555 and Alexa Fluor donkey anti-goat 488 in 1%BSA for 1
hour at room temperature in the dark. The mixture of secondary
antibody solution was decanted and washed three times with PBS for
5 minutes each in the dark. Slides were mounted with coverslip with
prolong Gold anti-fade mounting media with 4′,6-diamidino-2-
phenylindole (DAPI). Finally, coverslips were sealed with nail polish
to prevent drying and stored in the dark at 4°C. Double-label
immunofluorescence was analyzed by means of an Olympus BX60
microscope equipped with different excitation and emission filters at
×200 magnification.
Quantification of Immune Cells and Inflammatory Markers
Ten to 15 representative high-power field images at ×200magnification
were collected for each tumor using an Olympus BX60 microscope.
Each immune cell type was quantified in these images using NIS
Elements software. Similarly, expression of the inflammatory markers
was quantified by the sum density measurements of their expression
using NIS Elements software.
Statistical Analysis
Two-tailed Mann-Whitney analysis with a 95% confidence interval
was employed to establish statistical significance of differences between
tumors and control kidneys. A value of P b .05 was considered
statistically significant.Results
Increased Inflammatory Immune Cell Infiltration in WTs
CD3+ T cells and CD20+ B cells. Significant CD3+ T cell
infiltration was observed in 10 of 14 tumors relative to normal kidney
(representative images shown in Figure 1, A–C). This infiltration was
observed primarily in the stromal component of the tumor
(Figure 1C) rather than in the epithelial and blastemal components
(Figure 1B). Overall, tumors had 50 times more CD3+ T cells than
normal kidneys (Figure 1D). Similarly, B lymphocytes (CD20+) were
also present almost exclusively in the stroma of tumors (Figure 1, E–G).
Unlike T cell infiltration, however, which was observed in all tumors,
only 7 of 14 tumors analyzed showed substantial B cell infiltration. In
the other seven tumors, very few B cells were detected. Overall,
however, the average number of B cells infiltrated into tumors was
significantly higher than in control kidneys (Figure 1H).
CD68+ TAMs. Infiltration by TAMs was observed in 13 of 14
tumors analyzed (Figure 2, A–C). TAM infiltration was observed
primarily in stromal areas of tumors (Figure 2C), although some
infiltrating TAMs were found in tumor blastemal and epithelial
components (Figure 2B). Overall, there were significantly higher
numbers of TAMs in tumors than in control kidneys (Figure 2D).
The infiltration pattern and density of TAMs were uniform within
the tumor in all the tumor cases analyzed.
Myeloperoxidase-positive neutrophils. The infiltration pattern of
myeloperoxidase (MPO)–positive tumor-infiltrating neutrophils
(TINs) was similar to that of TAMs. In 12 of 14 tumors analyzed,
TIN infiltration was distributed in all regions of the tumor, but
predominantly in the tumor stroma, with very few TINs in normal
kidney sections (Figure 2, E–G). There were ~25 times more TINs in
tumors than in normal kidneys (Figure 2H).
Mast cells. MCs were found principally in the stroma and in very
small regions of the blastema; very few were found in normal tissues
(Figure 2, I–K). Although 12 of the 14 tumors evaluated showed MC
infiltration, the absolute numbers ofMCsweremuch less than the other












Figure 2. Infiltration of innate immune cells into WTs. (A–C) Representative infiltration by tumor-associated CD68+macrophages (TAMs)
on IHC staining of (A) normal kidney, (B) tumor blastema, and (C) tumor stroma. (D) Quantification of average number of TAMs per field in
normal kidneys (K) and tumors (T). (E–G) Representative images of TINs (MPO-positive) on IHC analysis of (E) normal kidney, (F) tumor
blastema, and (G) tumor stroma. (H) Quantification of average number of TINs per field in normal kidneys and tumors. (I–K) Representative
MC staining in (I) normal kidneys, (J) tumor blastema, and (K) tumor stroma. (L) Quantification of average number ofMCs per field. (M) Higher
magnification images of MC infiltration in blastema and stroma. *P ≤ .05, **P ≤ .01.
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Higher magnification of MCs infiltrating the blastema and stroma is
shown in Figure 2M.
Therefore, both adaptive and innate immune cells were present in
tumors at amuch higher frequency than in normal kidneys. Comparison of
the various infiltrative inflammatory immune cells in tumors showed that
the degree of TAM infiltration was significantly higher than the degree of
infiltration by the other cells (Figure 3). Infiltration pattern of various
inflammatory immune cells in different parts of the tumorwas summarized
in Table W2.
Overexpression of Inflammatory Protein Markers in WTs
Cyclooxygenase-2. Positive immunoreactivity for the COX-2
protein was observed in all tumors assessed relative to normal kidney
(Figure 4, A–C). In most tumors, weak to moderate cytoplasmic COX-
2 expression was observed in blastemal and epithelial components and
very intense nuclear staining was observed in the tumor stroma
(Figure 4C), although some of the tumors also showed intense
cytoplasmic expression in blastemal and epithelial cells (not shown).
Normal kidney samples showed weak to moderate staining in the
cytoplasm of some tubular epithelial cells (Figure 4A) and very weak or
no staining in renal interstitial cells or glomeruli. The sum density ofCOX-2 expression was significantly higher (about five times) in tumors
than in normal kidneys (Figure 4D).
Hypoxia-inducible factor 1. Although very little HIF-1 expression
was noted in normal kidney slides (Figure 4E), seven of the seven tumors
evaluated had cytoplasmic granular staining and membranous expression
in blastemal and epithelial cells (Figure 4F), with very prominent nuclear
localization ofHIF-1 protein expression in the tumor stroma (Figure 4G).
The density of HIF-1 expression in tumors was significantly higher than
that in control kidneys (Figure 4H). The stromal expression ofHIF-1 was
similar to the COX-2 expression pattern (Figure 4, C and G).
Phosphorylated Extracellular Signal–Related Kinases 1 and 2. Cyto-
plasmic expression of p-ERK1/2 in normal kidney was negligible
(Figure 4I). In contrast, prominent nuclear p-ERK1/2 staining was
observed in 10 of the 14 tumors analyzed. Although some expression in
blastemal cells (Figure 4J) was observed, p-ERK1/2 expression was
primarily localized to tumor stroma (Figure 4, K and L). No p-ERK1/2
expression was observed in the epithelial component of tumors (not
shown). Expression of p-ERK1/2 was significantly higher in tumors
than in control kidneys (Figure 4L). The stromal expression pattern of
p-ERK1/2 was similar to those of COX-2, HIF-1, and VEGF.
Phosphorylated STAT3. p-Stat3 expression was predominantly
confined to the nucleus, with almost undetectable cytoplasmic staining
Figure 3. Proportions of various inflammatory immune cells'
infiltration into WTs. Infiltration was quantified, and each different
immune cell type was designated with a distinct symbol. Infiltration
of TAMs was significantly greater than that of any other immune
cell type. **P ≤ .01, ***P ≤ .001; ns, not significant.
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was detected in three of the tumors. Almost all p-Stat3 expression was in
blastema (Figure 4N) or stroma (Figure 4O). Very little or no p-Stat3
expression was observed in the epithelial component of the tumors (not
shown). p-Stat3 expression was significantly higher in tumors than in
normal kidney (Figure 4P).
Inducible nitric oxide synthase. No significant immunoreactivity for
iNOSwas detected in the control kidney sections (Figure 5A). In contrast,
very diffuse cytoplasmic staining was observed in blastemal cells
(Figure 5B) and very intense nuclear and cytoplasmic staining was
observed in the tumor stroma (Figure 5C) in 11 of the 13 tumors. No
iNOS expression was observed in two tumors. Overall, iNOS expression
was significantly higher in tumors than in control kidneys (Figure 5D).
Nitrotyrosine. NT expression was very low in control kidneys
(Figure 5E). In all 13 tumors analyzed, the blastemal components
displayed diffuse cytoplasmic staining forNT (Figure 5F), whereas stromal
components displayed both nuclear and cytoplasmic staining for this
marker (Figure 5G).NTexpression in tumorswas significantly higher than
in control kidneys (Figure 5H).
Vascular endothelial growth factor. In normal kidneys, VEGF
expression was observed in proximal and distal convoluted tubules
(Figure 5I). VEGF expression was observed in the stroma of all 13
tumor specimens analyzed (Figure 5K). It also was observed, but to a
lesser degree, in blastemal (Figure 5J) and epithelial (data not shown)
components of the tumors. This pattern of VEGF expression was
similar to those of COX-2 (Figure 4C) and HIF-1 (Figure 4G). The
VEGF expression in tumors was significantly higher than that in
control kidney sections (Figure 5L). Expression of various inflam-
matory markers in different parts of the tumor was summarized in
Table W3. Though tumors used in the current study were different
stages of WT disease, we did not notice any difference in the
infiltration of inflammatory cells and expression pattern of different
inflammatory markers.
Characterization of Inflammation in Mouse Tumors
The characterization of inflammatory marker studies was extended
to the mouse model of WT to confirm their expression. Similar to
human tumors, very robust expression of COX-2 was observed in
mouse tumors (Figure 6B) compared to mouse control kidneys
(Figure 6A). Similarly, increased TAM (F4/80) infiltration was
observed in mouse tumors (Figure 6D) compared to control kidneys
(Figure 6C).Expression Pattern of Inflammatory Markers in the Tumor
Stroma Similar to that of TAM Recruitment
The expression of the inflammatory markers COX-2, HIF-1,
iNOS, p-ERK1/2, and VEGF was predominantly localized to tumor
stroma, similar to the localization of TAMs (Figures 1–5 and W1).
The co-distribution of major inflammatory marker COX-2 with
TAM infiltration in the tumor stroma was analyzed by double
immunofluorescence analysis (Figure 7). The COX-2 expression
(Figure 7, B and D) and TAM infiltration (Figure 7, C and D) was
almost undetectable in control kidney samples (Figure 7, A–D), but
there was very prominent expression of COX-2 (Figure 7, F and H)
and very huge infiltration of TAMs (Figure 7, G and H) in the tumor
stroma was noticed. This suggests that infiltration of inflammatory
immune cells and the expression of inflammatory markers in the
tumor stroma are related.
Discussion
While it has been previously established that an inflammatory
microenvironment plays a significant role in the establishment
and progression of adult-onset cancers, the potential contribution
of the inflammatory microenvironment in childhood cancers has
not yet been adequately addressed. We have investigated the role
of the inflammatory microenvironment in a panel of 14 WTs, a
pediatric cancer of the kidney. Our qualitative and quantitative
IHC assessment of immune cells and inflammatory protein
markers in WT revealed infiltration of both adaptive and innate
immune cells. The extent of infiltration varied among tumors
and also among histologically distinct regions within the same
tumor. Interestingly, adaptive immune cells (T and B cells) were
localized predominantly to the tumor stroma. In contrast, innate
immune cells (TAMs, TINs, and MCs), while localized
predominantly in the tumor stroma, were also present in all
other regions of the tumor.
In our panel of WTs, we also observed increased expression of
inflammatory proteins such as VEGF, HIF-1, and COX-2, which
have previously been noted to be elevated in WT [5,7,8], and iNOS
and NT, which had not been noted before in these tumors. The
majority of these inflammatory proteins were, like the immune cells,
primarily localized to the tumor stroma. This observation suggests a
correlation between the infiltrating immune cells and the activated
cytokines and chemokines. The co-localization of the inflammatory
proteins and the TAMs was especially striking, as TAM was the
predominant type of infiltrating immune cell in WTs in the present
study. This TAM infiltration was further confirmed (F4/80
expression) in the mouse model of WT. TAM infiltration is known
to be induced by COX-2 in the tumor microenvironment [10],
especially in the tumor stroma, and TAMs can also induce expression
of COX-2 [11]. Our double immunofluorescence analysis of COX-2
and TAMs in the tumor stroma supports the co-distribution of these
inflammatory markers and suggests that these inflammatory markers
may activate each other in the tumor microenvironment.
Studies have shown that TAMs are also involved in the
production of proangiogenic factors transforming growth factor β
and VEGF [12,13] and of immunosuppressive chemokines and
cytokines such as interleukin 10 and prostaglandin E2, which
contribute to tumor angiogenesis [12,14–16]. Thus, the TAM
infiltration we observed in our panel of WTs may play a significant
role in the increased VEGF expression also seen in these tumors and



















Figure 4. Overexpression of inflammatory markers in WTs. (A–C) Representative COX-2 expression in (A) normal kidneys, (B) tumor
blastema/epithelia, and (C) tumor stroma. (D) Quantification of sum density of COX-2 expression per field in normal kidneys (K) and tumors
(T). (E–G) Representative HIF-1 expression in (E) normal kidneys, (F) tumor blastema/epithelia, and (G) tumor stroma. (H) Sum density of
HIF-1 per field in normal kidneys and tumors. (I–K) Representative p-ERK1/2 expression in (I) normal kidneys, (J) tumor blastema/epithelia,
and (K) tumor stroma. (L) Sum density of p-ERK1/2 expression per field in normal kidneys and tumors. (M–O) Representative p-Stat3
expression in (M) normal kidneys, (N) tumor blastema/epithelia, and (O) tumor stroma. (P) Sum density of p-Stat3 expression per field in
normal kidneys and tumors. Negative controls expressed none of these markers. *P ≤ .05, **P ≤ .01.
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cytes in a small group of fiveWTs and noted the presence of T cells and
macrophages in these tumors [6].We have verified the presence of these
immune cells in our larger panel of tumors and have expanded this
analysis to include B cells, TINs, and MCs as well as inflammatory
markers and have established the localization of these immune cell types
and inflammatory markers within the tumors.
As already noted, our study is unique in the demonstration of
expression of iNOS and NT in the tumor stroma in WTs. Increased
expression of iNOS and COX-2 has been reported in various other
tumors [17], and other studies have demonstrated a correlation between
the expression of iNOS andNT and that of COX-2 [18] and their spatial
co-localizationwithTAM infiltration andVEGF expression [19,20].Our
data suggest a role for TAMs and COX-2 expression in the up-regulation
of expression of iNOS and NT in the tumor stroma. Furthermore, the
abundant expression of COX-2 along with iNOS and NT in the tumor
stroma may have induced HIF-1 expression in the tumors, and this, in
turn, may also upregulate the expression of VEGF.
One of the predominant inflammatory protein markers over-
expressed in all of our WTs was COX-2, which was highly expressed
in the tumor stroma and, to a lesser degree, in all other tumorcomponents. The COX-2 expression was further confirmed in the
mouse model of WT, which has shown a similar expression pattern
with the human tumors. This spatial expression is in marked contrast
to the findings of previous studies that reported moderate to strong
cytoplasmic expression of COX-2 in blastemal and epithelial
components of the tumors but no expression in the tumor stroma [8].
Various mechanisms could be responsible, individually or in
combination, for the abundant COX-2 expression in WTs. First, the
infiltrating immune cells themselves could be overexpressing COX-2.
Second, tumor fibroblasts could be generating COX-2 in response to
macrophage infiltration or the inflammatory tumor microenviron-
ment. Third, COX-2 expression in these tumors may be induced by
fetal mitogen IGF2 through the Ras/Raf/Mitogen-activated protein
kinase kinase also known as MEK/ERK pathway, as has been reported
in human keratinocytes [21]. Overexpression of IGF2 has been
reported in various cancers [22–25], including 70% of WTs [26,27].
We have previously reported upregulated p-ERK1/2 expression in
mouse WTs engineered to overexpress IGF2 and also in human WTs
[9], suggesting a role for ERK signaling in WT development. The
robust expression of COX-2 and p-ERK1/2 we observed in the















Figure 5. TAM-induced expression of inflammatory markers in WTs. (A–C) Representative iNOS expression in (A) normal kidneys, (B) tumor
blastema/epithelia, and (C) tumor stroma. (D) Quantification of sumdensity of iNOS expression per field in normal kidneys (K) and tumors (T).
(E–G) Representative NT expression in (E) normal kidneys, (F) tumor blastema/epithelia, and (G) tumor stroma. (H) Sum density of NT
expression per field in normal kidneys and tumors. (I–K) Representative VEGF expression per field in (I) normal kidneys, (J) tumor blastema/







Figure 6. Overexpression of major inflammatory marker COX-2 and infiltration of predominant inflammatory immune cells, TAMs (F4/80+ve
macrophages), in themousemodel ofWT (A–D). Representative COX-2 expression (×200) in (A) normalmouse kidney and (B) mouse tumor.
(C and D) Representative TAM infiltration (×400) in (C) normal kidney and (D) mouse tumor.
490 Inflammatory Microenvironment in Wilms Tumors Maturu et al. Translational Oncology Vol. 7, No. 4, 2014IGF2 over expression in WTs is COX-2 up-regulation and
promotion of an inflammatory microenvironment and that this
effect is mediated by enhanced p-ERK signaling.COX-2 can also activate the expression of HIF-1 through its
enzymatic product prostaglandin E2 [21,28]. The expression of












Figure 7. Expression pattern of major inflammatory marker COX-2 with TAM infiltration in the tumor stroma. To characterize the similar
localization of these two markers in the tumor stroma, double immunofluorescence staining was performed (A–H). Though in the control
kidneys staining for COX-2 (B and D) and TAMs (C and D) was not observed (A–D), in the tumor stroma, COX-2 (F and H) expression was
observed where predominant infiltrating immune cells, TAMs (G and H), were infiltrated (E–H).
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with granular cytoplasmic and membranous expression in blastemal
and epithelial regions, which is consistent with a previous report [5].
COX-2 activation of HIF-1 can also occur through hypoxia [5] or
hypoxia-independent mechanisms [29], the latter involving p-ERK1/2
[30]. As already noted, we observed expression of p-ERK1/2 in a
majority of tumors in the present study and also in our mouse model of
WT [9]. HIF-1 can also directly upregulate expression of COX-2
during hypoxia [31] and thus form a feedback loop to continually
activate the COX-2 pathway. Hence, we speculate that COX-2 in this
WT microenvironment may drive the inflammation and upregulate
the aforementioned downstream targets.
Thus, the current work represents a qualitative, quantitative, and
spatial assessment of various inflammatory immune cells and
inflammatory protein markers in WT. The correlation and
localization of TAMs in the tumor stroma with expression of various
inflammatory protein markers, such as COX-2, HIF-1, p-ERK1/2,
iNOS, and NT, suggest a functional association of TAM infiltration
with the overexpression of these markers (our double immunofluo-
rescence data confirmed the same) and vice versa in WTs and
demonstrate the existence of a highly inflammatory microenviron-
ment in this disease. Overexpression of inflammatory markers in
tumors, in particular COX-2, has provided a rationale for their
targeting in prevention and treatment of many cancers [32–36], by
COX-2–specific inhibitors alone [37–39] or in combination with
other inhibitors [40,41]. The current work suggests that such an
approach may also be of utility for WTs.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.neo.2014.05.008.
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